You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

~ Buy the INVOKANA (canagliflozin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR INVOKANA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for INVOKANA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01877889 ↗ A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers Completed Janssen-Cilag International NV Phase 1 2013-07-01 The purpose of this study is to compare the pharmacodynamics (ie, how the drug affects the body) of canagliflozin with the pharmacodynamics of dapagliflozin.
NCT01916863 ↗ Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects Completed Lexicon Pharmaceuticals Phase 1 2013-08-01 The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.
NCT02009488 ↗ Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Completed Janssen Research & Development, LLC Phase 1 2014-09-08 The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic (blood sugar) control on metformin monotherapy or on combination therapy with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
NCT02243202 ↗ Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants Completed Janssen Research & Development, LLC Phase 2 2014-09-01 The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for INVOKANA

Condition Name

Condition Name for INVOKANA
Intervention Trials
Diabetes Mellitus, Type 2 6
Type 2 Diabetes 3
Obesity 3
Heart Failure 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for INVOKANA
Intervention Trials
Diabetes Mellitus 12
Diabetes Mellitus, Type 2 11
Heart Failure 3
Kidney Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for INVOKANA

Trials by Country

Trials by Country for INVOKANA
Location Trials
United States 48
United Kingdom 3
Germany 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for INVOKANA
Location Trials
Texas 4
Massachusetts 4
Ohio 3
Florida 3
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for INVOKANA

Clinical Trial Phase

Clinical Trial Phase for INVOKANA
Clinical Trial Phase Trials
Phase 4 10
Phase 3 2
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for INVOKANA
Clinical Trial Phase Trials
Completed 11
Recruiting 4
Active, not recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for INVOKANA

Sponsor Name

Sponsor Name for INVOKANA
Sponsor Trials
Janssen Scientific Affairs, LLC 7
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
Janssen Research & Development, LLC 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for INVOKANA
Sponsor Trials
Other 32
Industry 14
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.